Psychotropic drugs in child and adolescent psychiatry - a new era on the horizon

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2395-2397

  Rothenberger, Aribert ^a   Gerlach, Manfred ^b   Dittmann, Ralf W ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ADOLESCENT; ATTENTION DEFICIT DISORDER; CHILD; CHILD PSYCHIATRY; COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; EDITORIAL; HEALTH CARE SYSTEM; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

ADOLESCENT; CHILD; DRUG UTILIZATION; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 77955640580     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959863     Document Type: Editorial

References (30)

1. Vitiello B. An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 2008; 20(2): 121-6.
2. Mitchell B, Carleton B, Smith A, Prosser R, Brownell M, Kozyrskyj A. Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces. Can J Psychiatry 2008; 53: 152-9.
3. Newcorn JH, Sutton VK, Zhang S, et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; (in press).
4. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European guideline. Eur Child Adolesc Psychiatry 2006; 15: 476-98.
5. Cornforth C, Sonuga-Barke E, Coghill D. Stimulant drug effects on attention-deficit/hyperactivity disorder: a review of the effects of age and sex of patients. Curr Pharm Design 2010; 16(22): 2424-33.
6. Henschel AD, Rothenberger LG, Boos J. Randomized clinical trials in children - Ethical and methodological issues. Curr Pharm Design 2010; 16(22): 2407-15.
7. Wolfarth T, Kalverdijk L, Rademaker C, et al. Psychopharmacology for children: from off label use to registration. Eur Neuropsychopharmacol 2009; 19(8): 603-8.
8. Parens E, Johnston J. Understanding the agreements and controversies surrounding childhood psychopharmacology. Child Adolesc Psychiatry Ment Health 2008; 2(1): 5.
9. Fanton J, Gleason MM. Psychopharmacology and preschoolers: a critical review of current conditions. Child Adolesc Psychiatr Clin N Am 2009; 18(3): 753-71.
10. Koelch M, Ludolph AG, Plener PL, et al. Safeguarding children's rights in psychopharmacological research: ethical and legal issues. Curr Pharm Design 2010; 16(22): 2398-2406.
11. Chacko A, Newcorn JH, Feirsen N, et al. Improving medication adherence in youth with ADHD: review and recommendations. Curr Pharm Design 2010, 16(22): 2416-23.
12. Uebel H, Albrecht B, Kirov R, et al. What can actigraphy add to the concept of labschool design in clinical trials? Curr Pharm Design 2010; 16(22): 2434-42.
13. Schlander M. The pharmaceutical economics of child psychiatric drug treatment. Curr Pharm Design 2010; 16(22): 2443-61.
14. Polanczyk G, Bigarella MP, Hutz MH, et al. Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Design 2010; 16(22): 2462-73.
15. Bock N, Gerlach M, Rothenberger A. Postnatal brain development and Psychotropic drugs. Effects on animals and animal models of depression and attention-deficit/hyperactivity disorder. Curr Pharm Design 2010; 16(22): 2474-83.
16. Malhotra S, Subodh BN. Informed consent & ethical issues in paeditric psychopharmacology. Indin J Med Res 2009; 129(1): 19-32.
17. Reeves G, Anthony B. Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders: implications of access, effectiveness, and contextual treatment. Paediatr Drugs 2009; 11(3): 165-9.
18. Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behaviour problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009 (in press).
19. Svanborg P, Thermlund G, Gustaffson PA et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009; 18(4): 240-9.
20. Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olazapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19(5): 539-45.
21. Wilens TE. Combined pharmacotherapy in pediatric psychopharmacology: friend or foe? J Child Adolesc Psychopharmacol 2009; 19(5): 483-484.
22. Quintana H, Cherlin E, Duesenberg DA, et al. Transition from methylphendiate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder - a preliminary tolerability and efficacy study. Clin Ther 2007; 29(6): 1168-77.
23. Hoare P, Remschmidt H, Medori R, et al. 12-month efficacy and safety of OROS((R)) MPH in children and adolescents with attentiondeficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005; 14: 305-9.
24. Remschmidt H, Hoare P, Ettrich C, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS((R)) MPH Results of a 3-week open-label study. EurChild Adolesc Psychiatry 2005; 14: 297-304.
25. Potter MP, Liu HY, Monuteaux MC, et al. Prescribing patterns for treatment of pediatric bipolar disorder in a specialty clinic. J Child Adolesc Psychoharmacol 2009; 19(5): 529-38.
26. Essok SM, Covell NH, Leckman-Westin E, et al. Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. Psychiatr Serv 2009; 60(12): 1595-602.
27. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19(5): 501-10.
28. Mehler-Wex C, Kölch M, Kirchheimer J, et al. Therapeutic drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacology. Child Adolesc Psychiatry Mental Health 2009; 3: 14.
29. Leckman JF, Yazgan Y. Editorial: developmental transitions to psychopathology: from genomics and epigenomics to social policy. J Child Psychol Psychiatry 2010; 51(4): 333-40.
30. Rey MR, Walter G, Soh N. Complementary and alternative medicine (CAM) treatments and pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2008; 47(4): 364-8.